Biotechnology - Licensing, Gilead Sciences


Current filters:

LicensingGilead Sciences

Popular Filters

MacroGenics in deal potentially worth $1 billion with Gilead for DART products


Privately held US biotech firm MacroGenics has entered into a license agreement with Gilead Sciences…

BiotechnologyGilead SciencesLicensingMacroGenicsResearch

Gilead partners to provide low-cost emtricitabine-based ARVs in developing countries


Gilead Sciences (Nasdaq: GILD), together with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab…

Anti-viralsBiotechnologyEmtricitabineGilead SciencesGlobalLicensingMylan LaboratoriesPharmaceuticalPricingProductionRanbaxy LaboratoriesStrides Arcolab

Gilead in another licensing deal with J&J unit for combo HIV/AIDS treatment


US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals,…

Anti-viralsBiotechnologycobicistatEmtrivaGilead SciencesJohnson & JohnsonLicensingPharmaceuticalPrezistaResearchTibotec

Bristol-Myers in licensing deal with Gilead for combination HIV pill


US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a licensing accord with biotech firm…

Anti-viralsBiotechnologyBristol-Myers SquibbcobicistatGilead SciencesLicensingPharmaceuticalReyataz

Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection


Gilead Sciences (Nasdaq: GILD) has entered into an exclusive worldwide license and collaboration agreement…

Anti-viralsBiotechnologyGilead SciencesGlobeImmuneLicensingResearchVaccines

Company Spotlight



Back to top